Next-Generation Biomanufacturing Market Share

  • Report ID: 5958
  • Published Date: Dec 01, 2025
  • Report Format: PDF, PPT

Next-Generation Biomanufacturing Market - Regional Analysis

North American Market Insights

North American next-generation biomanufacturing market is anticipated to hold the largest share of 36% during the foreseen period. Many of the top biopharmaceutical businesses in the world are based in North America, and they will probably use next-generation biomanufacturing technology to boost productivity and enhance their production processes. Along with having a robust R&D infrastructure, North America is home to numerous universities, research centers, and government organizations that are engaged in the development of novel biomanufacturing techniques and procedures. These organizations will probably be crucial in propelling the next-generation biomanufacturing market revenue expansion by creating innovative technologies and procedures that biopharmaceutical businesses and other end users can use.

APAC Market Insights

Next-generation biomanufacturing market in the Asia Pacific region is expected to hold a share of 28% during the forecast period. The increase in approved treatments and the growing demand for sophisticated biomanufacturing infrastructures that can support an increasing number of target indications for gene & cell therapies are factors that are attributed to the next-generation biomanufacturing market growth. The APAC region is witnessing unprecedented advances in medical treatments due to the substantial investments made by governments, pharmaceutical companies, and academic institutions. For instance, compared to 2008, greenfield FDI in the Asia-Pacific health sector decreased by 49% in 2021. However, with a 78% growth in the first quarter of 2022, things appear more promising. This is driving up demand for advanced biomanufacturing solutions.

Next-Generation Biomanufacturing Market Share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of next-generation biomanufacturing is evaluated at USD 27.65 billion.

The global next-generation biomanufacturing market size was worth over USD 25.71 billion in 2025 and is poised to grow at a CAGR of around 8.4%, reaching USD 57.6 billion revenue by 2035.

By 2035, the monoclonal antibodies segment in the next-generation biomanufacturing market is projected to secure a 48% share, underpinned by the accelerating adoption of next-generation biotechnological techniques for faster and more efficient mAb production.

Key players in the market include Sartorius AG, Regeneron Pharmaceuticals, Inc., GEA Group Aktiengesellschaft, PBS Biotech Inc., Applikon Biotechnology BV, Danaher Corporation, Merck KGaA, Shanghai Bailum Biotechnology Co., Ltd., Solaris Biotechnology Srl., ZETA GmbH.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos